Daniel Lurie is running a political masterclass. Majority approval rating across every major political group in the city. I would have thought this was ~impossible.

Excited to continue to support the team @nudge and @FEhrsam. Their team is genuinely super impressive. If you care about augmenting the human experience, go work there.

NewLimit paper just dropped @icmlconf showing our SOTA AI models can predict perturbed cell states. Helps to have the largest primary cell perturbation dataset in the world. Bonus points for one of the first demonstration of active learning in bio.

Using brainwaves to: ✔️ Play Call of Duty ✔️ Control robotic hands ✔️ Have a neural Mario Kart party ✔️ Regain one’s own natural voice       (+ more on eng and master plan) Hope you enjoy our update!

There are four horsemen of Foundation Models and only one is publicly listed. SEC has decided the revolution will not be ownable.

The capabilities compound. Software creation costs -> zero.

We’ve raised a $130 million Series B led by @kleinerperkins alongside new investors @natfriedman/@danielgross , @vkhosla, and @humancapital — joined by existing investors @foundersfund , @_DimensionCap, and @brian_armstrong (yes, the cofounders are doubling down). We also raised from some of the best angels who have supported the company over the first two years including @eladgil , @garrytan , @collision, @patrickc, @JoshuaKushner, @JTLonsdale, and @FEhrsam . NewLimit is building medicines to treat aging, the meta driver of nearly every major human disease. Once thought to be irreversible, the emerging science of epigenetic reprogramming has shown that aging is in fact malleable. This presents a therapeutic opportunity that is 100X larger than any biotech product that has come before. Our bet is that this combination of AI and scaled genomics can unlock medicines that give each of us more healthy years. We're deeply appreciative of investors who share our vision that addressing aging biology represents one of the most consequential projects of humanity.

.@newlimit is building medicines that target aging itself—not just individual diseases. Their approach is elegant and deeply technical: run the largest epigenetic reprogramming experiments and use the data to train frontier AI models. Proud to lead their Series B and back @brian_armstrong, @byersblake, @jacobkimmel, and Cathy O’Hare on this mission. Interested in joining their talented team on the journey? They’re hiring:

No code software creation is real.

A couple years ago @FEhrsam started talking to me about focused ultrasound for modulating the brain. I was initially too bandwidth pilled to see the near term opportunity. Over time I realized the power of their approach - manipulating brain states at larger scale than single neuron resolution. There are many times we are close to making the right decision for ourselves and need a little bit of help. On the verge of falling asleep, but can't quite doze off. On the verge of going for the vegetables but order the deep dish pizza instead. There can be massive life gains through even a subtle *Nudge* of our brain state. I'm excited to be along for the journey, even in just my small way, and get to watch @FEhrsam, @quintinfrerichs and Jeremy Barenholtz build @Nudge. Overall, bio remains underrated because nearly every bio company founded today works on very small patient populations. @nudge, @neuralink, @newlimit and a small group of others are building a new class of bio company that is built to enhance *everyone* - which is literally 100-1000x the patient population of a typical biotech company. I expect we will see many many more companies like this over the coming decade as the playbook is written by those audacious enough to start and talented enough to be successful.